Related Experiment Videos
Lipoprotein(a) and coronary thrombosis and restenosis after stent placement
A Wehinger1, A Kastrati, S Elezi
1Deutsches Herzzentrum and 1. Medizinische Klinik rechts der Isar, Munich, Germany.
Insights
High lipoprotein(a) levels did not increase thrombotic or restenotic events after coronary stent implantation. This study found no adverse impact on one-year outcomes for patients with elevated lipoprotein(a).
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Lipid Metabolism
Background:
- Lipoprotein(a) is implicated in atherogenesis and post-angioplasty complications.
- The clinical significance of elevated lipoprotein(a) in coronary stent recipients remains unclear.
- Understanding lipoprotein(a)'s role is crucial for managing cardiovascular risk.
Purpose of the Study:
- To prospectively evaluate the association between high lipoprotein(a) levels and adverse events post-coronary stent implantation.
- To determine if elevated lipoprotein(a) influences thrombotic and restenotic events.
- To assess the impact of high lipoprotein(a) on one-year clinical and angiographic outcomes.
Main Methods:
- Prospective study of 2,223 patients with successful coronary stent placement.
- Patients categorized into high (highest quintile, n=457) and low (lower four quintiles, n=1,766) lipoprotein(a) groups.
- Primary endpoints: angiographic restenosis at 6 months and event-free survival at 1 year. Secondary endpoint: angiographic stent occlusion.
Main Results:
- Early stent occlusion: 0.9% in high vs. 2.1% in low lipoprotein(a) groups (OR 0.41).
- Angiographic restenosis: 33.2% in high vs. 32.7% in low lipoprotein(a) groups (OR 1.02).
- One-year event-free survival: 73.0% in high vs. 74.8% in low lipoprotein(a) groups (p=0.45).
Conclusions:
- Elevated lipoprotein(a) levels did not significantly affect one-year clinical or angiographic outcomes after coronary stenting.
- Thrombotic events and restenosis rates were not adversely influenced by high lipoprotein(a) levels.
- The study suggests lipoprotein(a) may not be a significant predictor of adverse events in this patient cohort.
Objectives:
The objective of this prospective study was to evaluate the relation between high lipoprotein(a) levels and thrombotic and restenotic events after coronary stent implantation.
Background:
Lipoprotein(a) may promote atherogenesis, coronary thrombosis and restenosis after balloon angioplasty, but the clinical significance remains unclear.
Methods:
The study included 2,223 consecutive patients with successful coronary stent placement. According to the serum level of lipoprotein(a), patients were divided in two groups: 457 patients of the highest quintile formed the high lipoprotein(a) group, and 1,766 patients of the lower four quintiles formed the low lipoprotein(a) group. Primary end points were the incidence of angiographic restenosis at six months and the event-free survival at one year. Secondary end point was the incidence of angiographic stent occlusion.
Results:
Early stent occlusion occurred in four of the 457 patients (0.9%) with high and 37 of the 1,766 patients (2.1%) with low lipoprotein(a) levels, odds ratio of 0.41 (95% confidence interval, 0.15 to 1.16). Angiographic restenosis occurred in 173 of the 523 lesions (33.2%) in the high lipoprotein(a) group and 636 of the 1,943 lesions (32.7%) in the low lipoprotein(a) group, odds ratio of 1.02 (0.83 to 1.25). The probability of event-free survival was 73.0% in the high lipoprotein(a) group and 74.8% in the low lipoprotein(a) group (p = 0.45). On the basis of the findings in the low lipoprotein(a) group, the power of this study to detect a 25% increase in the incidence of restenosis and adverse events in the group with elevated lipoprotein(a) was 90% and 75%, respectively.
Conclusions:
Elevated lipoprotein(a) levels did not influence the one-year clinical and angiographic outcome after stent placement. Thrombotic events and measures of restenosis were not adversely affected by the presence of high lipoprotein(a) levels.